Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTZ-1091
- Development stage
- Preclinical
- Lead developer
- NTZ Lab
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
NTZ-1091 is a small molecule lead compound developed by NTZ Lab, a research company based in Sofia, Bulgaria. It functions as a selective monoamine oxidase B (MAO-B) inhibitor and is specifically designed as a radioligand prototype for imaging and diagnostic applications in central nervous system (CNS) disorders. The compound features improved physicochemical properties intended to enhance target engagement and imaging quality. NTZ-1091 is being investigated for its potential in managing and diagnosing neurodegenerative and psychiatric conditions, including Parkinson's disease, Alzheimer's disease, dementia, and depression. It is currently in the preclinical stage of development.
02
Targets
MAOB (Monoamine oxidase B)
Beyond the preview
Go deeper on NTZ-1091.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTZ-1091.